GLOW 50 mg, GLOW 70 mg and the Preloaded Pen
The two vial formulations contain different proportions of GHK-Cu, BPC-157 and TB-500. Their milligram totals are container contents, not instructions for an individual administration.[3, 4]
50 mg
35 mg GHK-Cu
5 mg BPC-157
10 mg TB-500
70 mg
50 mg GHK-Cu
10 mg BPC-157
10 mg TB-500
3 mL
107 mg GHK-Cu
21.4 mg BPC-157
21.4 mg TB-500
GLOW 70 mg has a 5:1:1 mass ratio; GLOW 50 mg has a 7:1:2 ratio. The 50 mg vial is therefore not simply a smaller version of the 70 mg mixture. Increasing or decreasing an amount of either premix changes all three components together.
In the supplied vial certificates, TB-500 is identified as 43-residue thymosin beta-4. Keep that identity separate from products described as shorter fragments. A schedule for a different material cannot be matched by name alone.[3, 4]
The pen specification shown on this site describes a preloaded 3 mL solution at a nominal 50 mg/mL. Its declared component amounts are detailed below. These facts come from the supplied manufacturer excerpt, not from forum posts.[5]
GLOW Peptide Dosage: Numbers Found in Community Discussions
For the 50/10/10 mg formulation, online guides describe approximately 2.33 mg of total blend once daily. Public discussions also contain reports expressed as separate ingredient amounts, rather than one combined number.[1, 2, 7, 10]
| Amount described online | What the number represents | Evidence type |
|---|---|---|
| About 2.33 mg combined blend | Total amount discussed for a 50/10/10 mg mixture; not 2.33 mg of each ingredient.[1, 2] | Published online protocol |
| 2 mg GHK-Cu + 0.4 mg BPC-157 + 0.4 mg TB-500 | Ingredient amounts stated in a community discussion; their calculated sum is 2.8 mg.[7] | Public discussion / personal account |
| 2.5 mg GHK-Cu + 0.5 mg BPC-157 + 0.5 mg TB-500 | Amounts in a firsthand post; their calculated sum is 3.5 mg. Frequency was not clearly established in that post.[10] | First-person anecdote |
Total blend versus GHK-Cu alone
A post saying "2 mg GLOW" is ambiguous unless it identifies the material. It might refer to all ingredients together, or only to the GHK-Cu component. The distinction is substantial because a fixed-ratio blend includes the other components alongside it.
The component amounts in the table are retained as reported; the combined 2.8 mg and 3.5 mg figures are arithmetic sums. They do not independently verify what was in a contributor's vial, whether the product was authentic, or what was actually administered.
A clearly described amount is easier to interpret than an unexplained syringe-unit number. However, clear reporting still does not establish that the amount is appropriate for another person or another formulation.
Daily Use or Five Days On, Two Days Off?
Both daily use and five days on, two days off appear in public GLOW discussions. An eight-week account describes daily use without weekly breaks; another discussion includes people planning or changing between daily and five-days-per-week schedules.[8, 9]
Daily
Use on every day of the stated course. This is a reported frequency, not a finding that continuous exposure is safer or more effective.
5 on / 2 off
Five use-days and two non-use days within a week. This is different from taking a multi-week break after finishing a course.
Five use-days and seven use-days do not produce the same weekly amount when the amount per use stays constant. That is an arithmetic difference; it does not establish which schedule has a better clinical outcome. A skipped day also does not create a basis for adding a catch-up amount.
Morning, evening or split timing?
A firsthand account describes changing from one administration to split timing after nausea and dizziness. The same discussion mentions other measures and medical contact. It cannot establish that splitting prevents adverse effects or that the timing change caused improvement.[11]
The sources reviewed do not establish an optimal morning, evening or split schedule for this blend. A tolerable routine described by one contributor is not a general safety rule.
GLOW Cycle Length: What People Report
A cycle usually means a stated period of use followed by time off. In the material reviewed, descriptions range from shorter four-to-six-week courses to eight-to-twelve-week courses. Individual contributors also describe eight-week courses with four-week breaks.[2, 8]
| Reported course length | Reported time off | Context |
|---|---|---|
| 4-6 weeks[2] | 2-4 weeks | A shorter-course pattern published in an online protocol guide |
| 6-8 weeks[7] | 3-4 weeks | A community contributor describes this pattern |
| 8 weeks[8] | 4 weeks | A first-person account describes eight weeks on and four off |
| 8-12 weeks[2] | 4-8 weeks | An extended pattern described in an online guide |
These rows describe the source material; none is selected as the recommended course. They should not be combined into a new rule, such as using the longest reported course with the shortest reported break.
Why do people take a break?
Community explanations include observing whether perceived changes persist and concerns about repeated exposure. Copper-related reasoning also appears in online protocol material. Those explanations are not measurements demonstrating that a particular number of weeks resets risk or establishes safe repeat use.[2, 9]
The break is not a scientifically established "washout" simply because a guide calls it one. The duration needed to clear a substance, the duration of any biological effect, and a practical pause are different questions.
Course length is not a product expiry date
A plan lasting eight weeks does not establish that a mixed vial or opened cartridge is stable for eight weeks. Quantity remaining, chemical stability and microbiological quality must be considered separately. Do not use an anecdotal cycle as the storage limit for a product.
For observations about appearance and timing, see GLOW before and after. Personal outcome reports do not establish a minimum course required for results.
GLOW Reconstitution: Understanding the Numbers
Reconstitution turns a dry preparation into a solution. The online preparation example for a 70 mg blend describes 3.0 mL of bacteriostatic water and an approximate 23.3 mg/mL total concentration.[1, 2] This is a published example, not a validated preparation instruction for personal injection.
The arithmetic below assumes a final solution volume of 3.0 mL. A stated amount of liquid added and a measured final solution volume are not automatically identical.
| 70 mg formulation | Declared amount | Calculated at 3.0 mL final volume |
|---|---|---|
| GHK-Cu | 50 mg | 16.67 mg/mL |
| BPC-157 | 10 mg | 3.33 mg/mL |
| TB-500 | 10 mg | 3.33 mg/mL |
| Total blend | 70 mg | 23.33 mg/mL |
These values are calculated from the supplied 70 mg composition, assuming uniform dissolution and the stated final volume. Values are rounded. They describe concentration only; they do not select an administration amount.[4]
What changes when the volume changes?
Concentration equals amount divided by final solution volume. More final volume means a lower concentration for the same amount of material. The ingredient ratio is unchanged: dilution cannot selectively change one component of a premixed blend.
The 50 mg vial needs its own calculation using its 35/5/10 mg formulation. The preloaded pen is already a liquid. Neither should inherit a preparation instruction simply because all three products use the GLOW name.
Why a unit-only chart is incomplete
A device marking describes a measured volume or a device setting, not an ingredient mass by itself. The formulation, final concentration and actual device calibration must all be known before interpreting it. A screenshot containing only "units" is not a complete specification.
For laboratory preparation, use the product-specific handling instructions and approved procedure. The sample preparation described in a COA is part of analytical testing, not a customer injection recipe. Review the original documentation.
Injection Sites and Reactions in Community Reports
Public guides name the abdomen, thigh and upper arm as subcutaneous locations. First-person discussions also mention abdominal and upper-gluteal locations. These are descriptions of published practices, not a recommendation to administer the blend at any of those sites.[1, 8]
The material reviewed does not demonstrate that injecting near a joint, injury or cosmetic concern improves the outcome. A claimed purpose such as skin appearance does not establish that administration should take place near the face or under-eye area.
What about stinging, redness or feeling unwell?
Community accounts include local welts and sensitivity as well as nausea and dizziness. One contributor described persistent nausea and occasional dizziness emerging around the second week. Those anecdotes do not identify a single cause or measure how often reactions occur.[7, 11]
Changes in sensation are not a potency test, and discomfort is not evidence that a product is working. Do not treat a forum suggestion to dilute, split, escalate or "push through" as a substitute for medical assessment.
This page does not provide needle-placement instructions. See the research overview for the separate evidence question; a dosing anecdote is not a clinical result.
GLOW Autoinjector: Composition and Concentration
The supplied manufacturer specification for the 3 mL pen lists the amounts below and identifies safety data sheet PL-SDS-070. The liquid has a nominal combined concentration of 50 mg/mL.[5]
3 mL preloaded format| Component | Per 3 mL pen | Calculated per mL |
|---|---|---|
| GHK-Cu | 107 mg | 35.67 mg/mL |
| BPC-157 | 21.4 mg | 7.13 mg/mL |
| TB-500 | 21.4 mg | 7.13 mg/mL |
The displayed component amounts total 149.8 mg; the stated 150 mg total is nominal. The per-mL figures above are calculated from the displayed quantities, not an independently measured assay.
The stated proportions are approximately 5:1:1, corresponding to the 70 mg formulation rather than the 50 mg vial's 7:1:2 proportions. The pen specification describes bacteriostatic water with 0.9% benzyl alcohol in a glass cartridge; it is not a dry-powder reconstitution example.[5]
Concentration is not a click setting
The amount associated with a numbered pen setting depends on the actual device calibration. A syringe chart cannot be transferred to a pen dial, and a photograph does not establish output per click. Device-specific instructions must come from the applicable manufacturer documentation.
Compare product presentations on the GLOW product page. That comparison covers product specifications, not an individual treatment plan.
Storage After Mixing and Batch Documentation
| Material | Documented sealed-storage condition | Source |
|---|---|---|
| 50 mg and 70 mg dry vial lots | -20 °C, desiccated, protected from light | Named-lot certificates[3, 4] |
| Preloaded 3 mL pen | 2-8 °C, original carton, protected from light | Supplied manufacturer specification[5] |
These instructions apply to the named product and condition. Sealed dry-powder storage and sealed liquid storage are different specifications.
A preparation guide describes refrigeration for its mixed example and approximately four weeks of use. That is a guide's claim, not a lot-specific stability result for every GLOW preparation.[1] The exact diluent, container, handling and time after opening matter when evaluating the applicable product documentation.
Use a manufacturer-supported after-opening or after-preparation limit for the exact product. A dry-lot retest date and a multi-week cycle discussed online do not establish that limit.
Reported blend purity by RP-HPLC
Lot PL-2609-042Certificate PL-26-00042Open the original two-page report
Reported blend purity by RP-HPLC
Lot PL-2609-043Certificate PL-26-00043Open the original two-page report
The two supplied certificates report manufacturer in-house testing on the named vial lots. Purity and identity results describe the tested samples; they do not set a human dose or cycle.[3, 4] The original PDFs open in a new tab.
Open Quality + COA for the complete certificate library, report details and issuer-verification links.
GLOW Dosage and Cycle FAQ
What is the usual GLOW peptide dose?−
There is no validated usual dose established by the sources reviewed here. The reported-amounts section shows examples from protocol pages and selected community accounts. Those examples are not a prescription, an approved dosing range or evidence that one amount suits everyone.
Should GLOW be daily or five days per week?−
How long do community GLOW cycles last?−
Does an amount stated for GLOW 70 apply to GLOW 50?−
Does reconstitution change how much peptide is in the vial?−
Changing the final volume changes concentration, not the original ingredient mass. Preparation losses and actual measured content are separate analytical questions. The calculation on this page assumes the declared amount and uniform dissolution.
Can I use a vial chart for the autoinjector?−
Not as device instructions. The pen has its own liquid concentration and calibration requirements. A click or numbered setting needs an actual setting-to-volume specification, not a visual guess.
Can stinging or a reaction be fixed by following a forum tip?−
Where are the supporting GLOW pages?−
Use Benefits for ingredient research, Before & After for outcome claims, GLOW vs KLOW for formulations, and Quality + COA for the original documents.
Keep the formulation and the evidence together.
Use the exact product record to interpret a number. Use the research to assess a claim.
References and Product Documents
Product specifications, online protocol claims and community accounts have different evidential roles. The discussion sample is selective, not a systematic review or a survey of typical use. Mathematical totals and concentrations are our calculations, clearly identified in the article. No clinician review has been completed for this draft.
- 1PeptideDoseInfo - GLOW 70 mgOnline protocol, retained as a source of published claims, not clinical validation.
- 2Peptide Dosing Protocols - GLOW stackOnline guide explicitly describing community-derived schedules; not a clinical trial.
- 3GLOW 50 mg: original supplied COAManufacturer in-house document: lot PL-2609-042; certificate PL-26-00042. Unchanged PDF.
- 4GLOW 70 mg: original supplied COAManufacturer in-house document: lot PL-2609-043; certificate PL-26-00043. Unchanged PDF.
- 5Supplied autoinjector specificationManufacturer product-page excerpt supplied for this project; refers to PL-SDS-070. Not a clinical or dose-setting record.
- 6FDA: safety risks associated with nominated bulk substancesOfficial safety context for BPC-157 and injectable GHK-Cu. Fragment-specific statements are not applied to full-length thymosin beta-4.
- 7Community discussion: Glow tips?Selected visible comments: ingredient amounts, use frequency, course length and local reactions. Unverified personal reports, not a representative survey.
- 8Community discussion: GLOW protocolSelected visible first-person reports, including an eight-week course and four-week break. The thread later includes separate-component use; that is not treated as the same product.
- 9Community discussion: What is your GLOW cycle?Search-indexed excerpts reviewed for daily versus five-days-per-week discussion. Full live thread was not retrievable; no claim of exhaustive review.
- 10First-person GLOW ingredient-amount reportSearch-indexed post dated January 22, 2026. Reports 2.5 mg / 0.5 mg / 0.5 mg; frequency is not inferred. No outcome claim is adopted.
- 11Community account: Glow EffectsPersonal account of nausea/dizziness and changing timing, with other measures discussed. Not an adverse-event rate or evidence that timing changes solve symptoms.